Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Pacific Edge's shares outstanding for the quarter that ended in Mar. 2026 was 1,022.63 Mil.
Pacific Edge's quarterly shares outstanding
increased
from Sep. 2025 (1,022.14 Mil) to Mar. 2026 (1,022.63 Mil).
It means Pacific Edgeissued new shares from Sep. 2025 to Mar. 2026 .
Pacific Edge's annual shares outstanding
increased
from Mar. 2025 (811.92 Mil) to Mar. 2026 (1,022.63 Mil).
It means Pacific Edgeissued new shares from Mar. 2025 to Mar. 2026 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Pacific Edge Shares Outstanding (EOP) Related Terms
Pacific Edge Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Pacific Edge's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PEB vs TMO, DHR, IDXX: Shares Outstanding (EOP) Comparison
For the Diagnostics & Research subindustry, Pacific Edge's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Pacific Edge's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 1,022.63 Mil mean?
Pacific Edge (ASX:PEB) has a Shares Outstanding (EOP) of 1,022.63 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Pacific Edge and its competitors.
Is Pacific Edge's Shares Outstanding (EOP) too high?
Pacific Edge's current Shares Outstanding (EOP) is 1,022.63 Mil. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Shares Outstanding (EOP) compare to TMO and DHR?
Pacific Edge's Shares Outstanding (EOP) of 1,022.63 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Pacific Edge and its competitors. Pacific Edge's current Shares Outstanding (EOP) is 1,022.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.25 — trading 390% above its estimated fair value. The current Shares Outstanding (EOP) is 1,022.63 Mil. Pacific Edge's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Shares Outstanding (EOP) is 1,022.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.25 is trading 390% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
Shares Outstanding (EOP): 1,022.63 Mil
GF Value™: A$0.05 vs. price of A$0.25 (390% above fair value)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score
Get the complete analysis for ASX:PEB
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
